Resources
Bantam & Collaborators Published in Molecular Cancer Therapeutics, an AACR Journal
Targeting aggressive B-cell lymphomas through pharmacological activation of the mitochondrial protease OMA1 Abstract DLBCL are aggressive, rapidly proliferating tumors that critically depend on the ATF4-mediated integrated stress response (ISR) to adapt to stress caused by uncontrolled growth, such as hypoxia, amino acid deprivation and accumulation of misfolded proteins. Here we show that ISR hyperactivation is… Continue reading Bantam & Collaborators Published in Molecular Cancer Therapeutics, an AACR Journal
Bantam Pharma Featured in Nature BioPharma Dealmakers
BANTAM PHARMACEUTICAL TO PRESENT AT BIOTECH SHOWCASE™ 2023
Developing Novel Selective Modulators of Mitochondrial Dynamics (SeMMiDs)A differentiated therapeutic approach for treating aggressive cancer Raleigh, NC. January 9th, 2023 – Bantam Pharmaceutical, LLC announces that it is presenting at the Biotech Showcase taking place in San Francisco, the 9th-11th of January and virtually, on demand the 18th and 19th of January. Bantam Pharmaceutical is… Continue reading BANTAM PHARMACEUTICAL TO PRESENT AT BIOTECH SHOWCASE™ 2023
Bantam Pharmaceutical and Collaborators to Present New Data in Support of its Clinical Candidate BTM-3566 at Third AACR International Meeting – Advances in Malignant Lymphoma
RESEARCH TRIANGLE PARK, N.C., June 23, 2022 /PRNewswire/ — Bantam Pharmaceutical, a drug discovery and development company targeting selective modulation of mitochondrial dynamics in cancer, announced that new data on the mechanism of action of its lead clinical candidate BTM-3566 will be presented at the Third AACR International Meeting – Advances in Malignant Lymphoma taking place on the 23-26… Continue reading Bantam Pharmaceutical and Collaborators to Present New Data in Support of its Clinical Candidate BTM-3566 at Third AACR International Meeting – Advances in Malignant Lymphoma
Bantam Pharmaceutical and Collaborators to Present New Data in Support of its lead drug BTM-3566 at AACR Annual Meeting 2022
RESEARCH TRIANGLE PARK, N.C., April 8th, 2022 – Bantam Pharmaceutical, a drug discovery and development company targeting selective modulation of mitochondrial dynamics in cancer, will present new data on its lead drug candidate BTM-3566 at AACR 2022 taking place the 8th-13th of April in New Orleans. The data demonstrate that BTM-3566 co-opts a specific mitochondrial quality control… Continue reading Bantam Pharmaceutical and Collaborators to Present New Data in Support of its lead drug BTM-3566 at AACR Annual Meeting 2022
Data on Bantam Pharmaceutical’s Lead Drug, BTM-3566 Highlighted During Oral Session on Targeting Mitochondria Pathways in Lymphoid Cancers at the 63rd Annual ASH Meeting
BTM-3566 demonstrated robust therapeutic responses in Diffuse Large B-Cell Lymphoma models, both in vitro and in vivo RESEARCH TRIANGLE PARK, N.C., Dec. 13, 2021 /PRNewswire/ — Bantam Pharmaceutical, a drug discovery and development company targeting selective modulation of mitochondrial dynamics in cancer, announced that data on the activity and mechanism of BTM-3566, a novel, first-in-class oral compound… Continue reading Data on Bantam Pharmaceutical’s Lead Drug, BTM-3566 Highlighted During Oral Session on Targeting Mitochondria Pathways in Lymphoid Cancers at the 63rd Annual ASH Meeting
Bantam Patent Coverage through 2039
First Patents Published December, 2016 WO2016196644A1 Substituted pyrazole and pyrrole compounds and methods for using them for inhibition of initiation of translation and treatment of diseases and disorders relating thereto WO2018102453 Substituted pyrazole compounds and methods of using them for treatment of hyperproliferative diseases WO2018102452 Methods of using substituted pyrazole and pyrazole compounds and for… Continue reading Bantam Patent Coverage through 2039
Bantam Pharmaceutical Announces Data on its lead drug, BTM-3566 to be Presented at the 63rd Annual Meeting of the American Society of Hematology
Bantam Pharmaceutical Announces Data on its lead drug, BTM-3566 to be Presented at the 63rd Annual Meeting of the American Society of Hematology Oral Presentation Will Focus on InVitro and InVivo Responses to BTM-3566 in Diffuse Large B-Cell Lymphoma RESEARCH TRIANGLE PARK, N.C., November 18, 2021 — Bantam Pharmaceutical, a drug discovery and development company targeting selective modulation of mitochondrial dynamics… Continue reading Bantam Pharmaceutical Announces Data on its lead drug, BTM-3566 to be Presented at the 63rd Annual Meeting of the American Society of Hematology
Bantam Pharmaceutical Completes $25 Million Seed Funding
Bantam Pharmaceutical Completes $25 Million Seed Funding to Finalize Preclinical Development and Prepare for First in Humans Trials IND Application Expected in Early 2022 for Its Lead Product BTM-3566 Company Establishes Operations in the Research Triangle Park NEWS PROVIDED BY Bantam Pharmaceutical, LLC Sep 16, 2021, 08:00 ET Bantam plans to submit its Investigational New… Continue reading Bantam Pharmaceutical Completes $25 Million Seed Funding